288 related articles for article (PubMed ID: 37223096)
1. Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?
Sun T; Li D; Huang L; Zhu X
Front Immunol; 2023; 14():1141779. PubMed ID: 37223096
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
Read JA; Rouce RH; Mo F; Mamonkin M; King KY
Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
[TBL] [Abstract][Full Text] [Related]
4. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
5. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
6. Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective.
Si X; Gu T; Liu L; Huang Y; Han Y; Qian P; Huang H
Cancer Lett; 2022 Dec; 550():215920. PubMed ID: 36122628
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
9. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic CD34
Lipsitt A; Beattie L; Harstead E; Li Y; Goorha S; Maron G; Gottschalk S; Triplett B; Naik S
Pediatr Blood Cancer; 2023 Mar; 70(3):e30166. PubMed ID: 36565276
[TBL] [Abstract][Full Text] [Related]
11. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.
Wang L; Hong R; Zhou L; Wang Y; Lv Y; Ni F; Zhang M; Zhao H; Ding S; Chang AH; Xu H; Hu Y; Wei G; Huang H
Cytotherapy; 2023 Feb; 25(2):192-201. PubMed ID: 36496302
[TBL] [Abstract][Full Text] [Related]
12. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy.
Iqbal M; Bansal R; Yassine F; Gandhi S; Rosenthal A; Moustafa MA; Li Z; Craver EC; Mohty R; Murthy H; Ayala E; Tun H; Munoz J; Castro J; Lin Y; Kharfan-Dabaja MA
Transplant Cell Ther; 2022 Oct; 28(10):668.e1-668.e6. PubMed ID: 35842124
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.
Saleh K; Arbab A; Ghez D; Bigenwald C; Cotteret S; Marzac C; Pasquier F; Pilorge S; Saada V; Vergé V; Ribrag V; Castilla-Llorente C
Immunotherapy; 2023 Apr; 15(6):401-407. PubMed ID: 36950962
[TBL] [Abstract][Full Text] [Related]
14. Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.
Li H; Zhao L; Sun Z; Yao Y; Li L; Wang J; Hua T; Ji S; Wang S; Cheng H; Shi M; Li Z; Zeng L; Wu Q; Qiao J; Chen C; Zheng J; Cao J; Xu K
Front Immunol; 2022; 13():1019548. PubMed ID: 36330523
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study.
Gagelmann N; Wulf GG; Duell J; Glass B; van Heteren P; von Tresckow B; Fischer M; Penack O; Ayuk F; Einsele H; Holtick U; Thomson J; Dreger P; Kröger N
Blood Adv; 2023 Feb; 7(4):555-559. PubMed ID: 35696759
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report.
Baur R; Jitschin R; Kharboutli S; Stoll A; Völkl S; Büttner-Herold M; Schmidt D; Rösler W; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272307
[TBL] [Abstract][Full Text] [Related]
18. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
20. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
